[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: GEMCOVAC-19 (COVID-19 vaccine): In 12 to less than 18 years; GEMCOVAC-19 will be administered as a 2 dose schedule on Day 1 and 29 at 10 micrograms intramuscularly.In 5-11 years ; GEMCOVAC-19 will be assesseed in Phase II at 5 and 10 micrograms as a 2 dose regimen intramuscularly. In phase IIII(In 5-11 years); one dose will be selected to be administered as a 2 dose schedule intramuscularly.The study in each age group will last for 9 monthsControl Intervention1: COVAXIN\u00c2\u00ae: COVAXIN\u00c2\u00ae will be administered as a 2 dose schedule on Days 1 and 29 as 0.5 mL intramuscularly\t(In 12 to less than 18 years)Control Intervention2: Placebo: 0.9% NaCl will be administered as a 2 dose schedule on Days 1 and 29 as 0.5 mL intramuscularly (In 5 to 11 years)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: GEMCOVAC-19 (COVID-19 vaccine): In 12 to less than 18 years; GEMCOVAC-19 will be administered as a 2 dose schedule on Day 1 and 29 at 10 micrograms intramuscularly.In 5-11 years ; GEMCOVAC-19 will be assesseed in Phase II at 5 and 10 micrograms as a 2 dose regimen intramuscularly. In phase IIII(In 5-11 years); one dose will be selected to be administered as a 2 dose schedule intramuscularly.The study in each age group will last for 9 monthsControl Intervention1: COVAXIN\u00c2\u00ae: COVAXIN\u00c2\u00ae will be administered as a 2 dose schedule on Days 1 and 29 as 0.5 mL intramuscularly\t(In 12 to less than 18 years)Control", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: COVAXIN\u00c2\u00ae: COVAXIN\u00c2\u00ae will be administered as a 2 dose schedule on Days 1 and 29 as 0.5 mL intramuscularly\t(In 12 to less than 18 years)Control Intervention2: Placebo: 0.9% NaCl will be administered as a 2 dose schedule on Days 1 and 29 as 0.5 mL intramuscularly (In 5 to 11 years)", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2466, "treatment_name": "Gemcovac-19", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 1387, "treatment_name": "Covaxin", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]